监护室重症肺炎预后影响因素分析
Analysis of Prognostic Factors for Severe Pneumonia in Multiple Intensive Care Units
DOI: 10.12677/acm.2026.163864, PDF,   
作者: 张 蕾, 朱洪斌*:安徽医科大学第四附属医院呼吸内科,安徽 巢湖
关键词: 重症监护室重症肺炎预后Intensive Care Units Severe Pneumonia Prognosis
摘要: 目的:探讨重症肺炎患者预后不良的独立影响因素,为临床制定干预措施提供参考依据。方法:回顾性选取2023年5月1日至2025年5月1日在本院重症监护室、呼吸监护室和急诊监护室接受治疗的139例重症肺炎患者为研究对象,根据患者的临床预后结局分为预后良好组(n = 41)和预后不良组(n = 98)。比较两组患者的临床相关资料、呼吸道病原菌、监护室化验指标极值等,通过单因素及多因素Logistic回归分析筛选监护室重症肺炎患者预后影响因素;受试者工作特征曲线(ROC曲线)分析影响因素的预测效能。结果:与预后良好组对比,预后不良组的监护室住院时间、机械通气、血管置管、镇静镇痛、病原菌分型、铜绿假单胞菌感染、白细胞max、中性粒细胞计数max、淋巴细胞计数min、血小板计数min、降钙素原max、降钙素原min、D-二聚体max,差异均有统计学(P < 0.05)。多因素Logistic回归分析显示,机械通气(OR = 3.542, 95%CI = 1.295~9.688, P = 0.014)和血管置管(OR = 3.068, 95%CI = 1.127~8.347, P = 0.028)是监护室重症肺炎患者预后不良的独立危险因素;铜绿假单胞菌(OR = 0.289, 95%CI = 0.094~0.889, P = 0.030)和血小板计数min (OR = 0.995, 95%CI = 0.990~1.000, P = 0.041)是预后的独立保护因素。ROC曲线显示,血管置管单独预测监护室重症肺炎患者预后不良的曲线下面积(AUC)最大(0.710),机械通气的敏感度最高(87.80%),血小板计数min的特异度最高(78.00%);联合预测的AUC为0.802,敏感度为77.60%,特异度为73.20%。结论:在本研究队列中,需要机械通气、血管置管的监护室重症肺炎患者预后不良风险更高,铜绿假单胞菌感染及维持较高水平的血小板计数为预后保护因素,临床可通过严格把握机械通气指征、血管置管侵入操作、依据药敏结果精准抗感染、动态监测并维持血小板水平,制定个体化干预方案以改善患者预后。
Abstract: Objective: To investigate the independent influencing factors of poor prognosis in patients with severe pneumonia, and to provide references for formulating clinical intervention strategies. Methods: A total of 139 patients with severe pneumonia who received treatment in the ICU, RICU, and EICU of our hospital from May 1, 2023 to May 1, 2025 were retrospectively enrolled. According to clinical prognostic outcomes, patients were divided into the favorable prognosis group (n = 41) and the poor prognosis group (n = 98). Clinical data, respiratory pathogens, and extreme values of laboratory indicators during stay in multiple intensive care units were compared between the two groups. Univariate and multivariate Logistic regression analyses were performed to identify prognostic factors for severe pneumonia in patients from multiple intensive care units, and ROC curve was used to evaluate the predictive efficacy of these factors. Results: Compared with the favorable prognosis group, the poor prognosis group showed statistically significant differences in length of stay in multiple intensive care units, mechanical ventilation, vascular catheterization, sedation and analgesia, pathogen typing, Pseudomonas aeruginosa infection, maximum WBC, maximum NEU, minimum LYM, minimum PLT, maximum PCT, minimum PCT, and maximum D-dimer (P < 0.05). Multivariate Logistic regression analysis revealed that mechanical ventilation (OR = 3.542, 95%CI = 1.295~9.688, P = 0.014) and vascular catheterization (OR = 3.068, 95%CI = 1.127~8.347, P = 0.028) were independent risk factors for poor prognosis. In contrast, infection with susceptible strains of Pseudomonas aeruginosa (OR = 0.289, 95%CI = 0.094~0.889, P = 0.030) and minimum PLT (OR = 0.995, 95%CI = 0.990~1.000, P = 0.041) were independent protective factors. ROC curve analysis showed that vascular catheterization had the largest area under the curve (AUC = 0.710) for predicting poor prognosis alone, mechanical ventilation had the highest sensitivity (87.80%), and minimum PLT had the highest specificity (78.00%). The combined prediction model yielded an AUC of 0.802, with a sensitivity of 77.60% and a specificity of 73.20%. Conclusion: In this cohort, patients with severe pneumonia in multiple intensive care units requiring mechanical ventilation or vascular catheterization were at higher risk of poor prognosis. Infection with Pseudomonas aeruginosa and maintenance of a relatively high PLT were protective for prognosis. Clinically, individualized interventions can be developed to improve patient outcomes by strictly adhering to mechanical ventilation indications, standardizing invasive procedures such as vascular catheterization, implementing targeted anti-infection therapy based on drug sensitivity results, and dynamically monitoring and maintaining platelet levels.
文章引用:张蕾, 朱洪斌. 监护室重症肺炎预后影响因素分析[J]. 临床医学进展, 2026, 16(3): 924-932. https://doi.org/10.12677/acm.2026.163864

参考文献

[1] 王道才, 谭美春, 施巍, 等. 血清PSGL-1、HPT、sCD14-ST对重症肺炎患者病情进展和预后评估价值[J]. 临床肺科杂志, 2025, 30(8): 1170-1175.
[2] 刘晓, 王彤, 蒋怡芳, 等. 重症社区与医院获得性肺炎临床特征与预后分析[J]. 中国感染与化疗杂志, 2018, 18(2): 163-170.
[3] Nair, G.B. and Niederman, M.S. (2021) Updates on Community Acquired Pneumonia Management in the ICU. Pharmacology & Therapeutics, 217, Article ID: 107663. [Google Scholar] [CrossRef] [PubMed]
[4] 常越, 王金平. 亚胺培南西司他丁联合呼吸喹诺酮类药物治疗重症加强护理病房重症肺炎的临床疗效与安全性[J]. 中国药物经济学, 2024, 19(10): 81-83, 87.
[5] 于蕾, 姜薇薇, 李吉明. 老年急性缺血性脑卒中合并重症肺炎患者病原菌分布与T细胞亚群改变及预后[J]. 中华老年多器官疾病杂志, 2024, 23(9): 655-658.
[6] 中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南(2016年版) [J]. 中华结核和呼吸杂志, 2016, 39(4): 253-279.
[7] Ma, J., Li, L., Qie, X., Zhao, Q., Zhang, L., Xu, N., et al. (2023) Value of Combined Detection of PCT, CRP, and FIB in Differentiating Viral Infection from Bacterial Infection in Severe Pneumonia. Clinical Laboratory, 69, e230325. [Google Scholar] [CrossRef] [PubMed]
[8] 周敏, 王海波, 张强, 等. 重症肺炎伴ARDS患者的菌群分布及预后因素分析[J]. 中国城乡企业卫生, 2024, 39(9): 89-92.
[9] 李真, 张巧梅, 石瑞平, 等. 重症肺炎患者血清IL-17和TIM-4及TLR7水平变化及与预后的关系[J]. 感染、炎症、修复, 2025, 26(5): 334-338.
[10] 张婷婷, 王静, 杨丽. 老年重症肺炎病原菌分布及预后影响因素分析[J]. 中国卫生标准管理, 2025, 16(14): 91-95.
[11] 邓鑫. 重症监护室呼吸机相关性肺炎的影响因素及标准化护理对策研究[J]. 中国标准化, 2022(14): 246-249.
[12] 李帅, 张亚, 王静. 综合护理干预对降低ICU重症患者呼吸机相关性肺炎发生率的影响[J]. 中国医药指南, 2022, 20(17): 21-24.
[13] 朱景敏, 卢亚飞, 许敏霞, 等. 血液透析患者导管感染危险因素分析[J]. 中国现代医生, 2020, 58(22): 103-105, 109.
[14] Al-Hasan, M.N. and Rac, H. (2020) Transition from Intravenous to Oral Antimicrobial Therapy in Patients with Uncomplicated and Complicated Bloodstream Infections. Clinical Microbiology and Infection, 26, 299-306. [Google Scholar] [CrossRef] [PubMed]
[15] Alali, M., Mayampurath, A., Dai, Y. and Bartlett, A.H. (2022) A Prediction Model for Bacteremia and Transfer to Intensive Care in Pediatric and Adolescent Cancer Patients with Febrile Neutropenia. Scientific Reports, 12, Article No. 7429. [Google Scholar] [CrossRef] [PubMed]
[16] 沈林华. 铜绿假单胞菌感染性肺炎患者的病原菌特征和肺表面活性蛋白B基因多态性和疾病进展与抗菌疗效的关系[J]. 中国现代医生, 2022, 60(29): 52-56, 61.
[17] 田苍松. 感染铜绿假单胞菌肺炎患者的治疗和预后研究[J]. 中国医药指南, 2018, 16(24): 47-48.
[18] 齐亚平. 铜绿假单胞菌肺炎治疗和预后的临床研究[J]. 首都食品与医药, 2017, 24(2): 28-29.
[19] 王睦天, 赵启亮, 张慧琪, 等. 铜绿假单胞菌肺炎转重症的风险因素及中药干预效果回顾性分析[J]. 中国中医急症, 2023, 32(12): 2078-2081.
[20] Daikos, G.L., da Cunha, C.A., Rossolini, G.M., Stone, G.G., Baillon-Plot, N., Tawadrous, M., et al. (2021) Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas Aeruginosa. Antibiotics, 10, Article 1126. [Google Scholar] [CrossRef] [PubMed]
[21] 陈丽红, 肖曲香. 联合检测WBC、NLR、PLR、NEU%对急性加重期慢阻肺的预测价值[J]. 安徽医专学报, 2025, 24(4): 75-77.
[22] 陈秀琴, 黄玉麟, 汤俊. 重症肺炎患者血小板参数、OI值与患者治疗结局关系的多因素分析[J]. 临床和实验医学杂志, 2021, 20(11): 1195-1198.
[23] Middleton, E.A., Weyrich, A.S. and Zimmerman, G.A. (2016) Platelets in Pulmonary Immune Responses and Inflammatory Lung Diseases. Physiological Reviews, 96, 1211-1259. [Google Scholar] [CrossRef] [PubMed]
[24] Weyrich, A.S. and Zimmerman, G.A. (2013) Platelets in Lung Biology. Annual Review of Physiology, 75, 569-591. [Google Scholar] [CrossRef] [PubMed]
[25] Li, X., Iwai, T., Nakamura, H., Inoue, Y., Chen, Y., Umeda, M., et al. (2008) An Ultrastructural Study of Porphyromonas Gingivalis-Induced Platelet Aggregation. Thrombosis Research, 122, 810-819. [Google Scholar] [CrossRef] [PubMed]